The Company (Details) $ in Thousands		3 Months Ended
	Apr. 06, 2017	Mar. 31, 2017 USD ($) Systems Extension shares	Mar. 31, 2016 USD ($) shares	Dec. 31, 2016 USD ($)
Liquidity [Abstract]
Accumulated deficit		$ (212,810)		$ (210,575)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt		20,525		20,082
Earnings Per Share [Abstract]
Net loss			$ (1,437)
Gain on the change in fair value of the warrant liability		$ 132	(1,985)
Diluted earnings			$ (3,422)
Weighted average number of common and common equivalent shares outstanding [Abstract]
Basic number of common shares outstanding (in shares) | shares		2,176,731	2,067,931
Dilutive effect of warrants (in shares) | shares			593,654
Diluted number of common and common stock equivalent shares outstanding (in shares) | shares		2,176,731	2,661,585
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares		12,970,497	13,649,760
Subsequent Event [Member]
Business Acquisition [Line Items]
Reverse stock-split ratio	0.20
Ellipse [Member]
Business Acquisition [Line Items]
License agreement, number of additional years automatically extended		2 years
Monthly license fee		$ 33
License fee for initial term		$ 1,100
Esthetic Education, LLC [Member]
Business Acquisition [Line Items]
Agreement period		3 years
Number of extensions allowed | Extension		2
Period of extension		1 year
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 8)		$ 237		105
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 8)		0		0
Fair Value, Measurements, Recurring [Member] | Significant other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 8)		0		0
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 8)		$ 237		$ 105
XTRAC [Member]
Business Acquisition [Line Items]
Number of systems placed in dermatologists offices | Systems		791
Common Stock Equivalents of Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares		9,201,146	9,243,027
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares		2,406,625	3,365,690
Common Stock Equivalents of Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares		467,836	507,173
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) | shares		894,890	533,870